WO2011103789A1 - 复方丹参滴丸胶囊 - Google Patents
复方丹参滴丸胶囊 Download PDFInfo
- Publication number
- WO2011103789A1 WO2011103789A1 PCT/CN2011/071050 CN2011071050W WO2011103789A1 WO 2011103789 A1 WO2011103789 A1 WO 2011103789A1 CN 2011071050 W CN2011071050 W CN 2011071050W WO 2011103789 A1 WO2011103789 A1 WO 2011103789A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- capsule
- capsule shell
- borneol
- sanqi
- pills
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a medicine capsule preparation prepared by processing a capsule shell of different colors and materials.
- Compound Danshen Dripping Pill is a new generation of medicine for treating cardiovascular diseases. It is exclusively produced by Tianjin Tianshili Pharmaceutical Co., Ltd. Compound Danshen Dripping Pills are made with Danshen as the drug, Sanqi as the drug, and borneol as the adjuvant. It has the effect of promoting blood circulation, removing phlegm, relieving pain and aroma. It is mainly used for the treatment of cardiovascular diseases.
- the compound Danshen Dripping Pills in the domestic market are packaged in high-density polyethylene bottles in the specifications of 180 pills/bottle, 150 pills/bottle, 100 pills/bottle, and 60 pills/bottle. Take 10 pills each time you take it. However, this type of administration is less accepted abroad. In order to enter the international market, the applicant plans to further make the compound Danshen dripping pills into capsule preparations.
- capsule shells of different nature may have certain effects on the stability of medicines and foods.
- hard capsule shells sold on the market are generally divided into gelatin capsule shells and plant capsule shells. .
- the gelatin capsule shell is made of a protein product obtained by partially hydrolyzing and purifying collagen from the skin, bone and tendons of an animal, and the capsule shell contains a large amount of strontium.
- the fish gelatin capsule shell is a new type of gelatin capsule shell developed in recent years.
- the plant capsule shell is a capsule shell made of a plant-derived raw material (the raw material contains a polysaccharide and an essential component of a plant cell wall), for example, hydroxypropylmethylcellulose (HPMC).
- the currently common plant capsule shells are a plant capsule shell made of pullulan, a plant capsule shell made of seaweed polysaccharide, and a plant capsule shell made of hydroxypropylmethylcellulose.
- the transparent capsule shell is more likely to enhance the affinity of Chinese medicine to customers, enhance sensory awareness, and is widely welcomed by the international market.
- the transparent capsule shells of different colors reflect light of different wavelength bands, which causes the medicine to receive light of different wavelengths. Therefore, the transparent capsule shells of different colors have certain influence on the stability of the drug itself.
- capsule shells of different materials have different effects on the stability of the drug due to differences in hygroscopicity, stability, and physicochemical properties of the material itself.
- the applicant has studied the effect of the capsules of different materials and colors on the stability of the drug after a long period of research, and the capsule shell which is beneficial to the stability of the drug is selected through screening.
- the object of the present invention is to provide a compound Danshen dripping pill capsule with good stability.
- the capsule preparation of the present invention is made of a drug and a capsule shell, and the medicine is filled in a capsule shell, wherein the capsule shell is a colored capsule shell, and the medicine is a compound Danshen dripping pill.
- the color of the capsule shell is preferably: an orange-yellow-green-blue capsule shell having a corresponding wavelength range of 446 nm to 620 nm.
- the preferred capsule shell color is: orange, corresponding wavelength range is 592nm-620nm; blue, corresponding wavelength range It is 446nm-500nm; yellow, corresponding wavelength range is 577nm-592nm; and green, corresponding wavelength range is 500nm-577nm.
- the most preferred color is yellow-based capsule shells, corresponding to the wavelength range 577n m -592nm; and green lines, corresponding to a wavelength range of 500nm-577nm.
- the capsule shell is selected from the group consisting of a gelatin capsule shell and a plant capsule shell.
- the capsule shell is preferably a plant capsule shell.
- the compound Danshen dripping pill of the invention is prepared from Danshen, Sanqi and borneol.
- the compound danshen dropping pills of the present invention are made of the following weight percentages of the drug substance relative to the total weight of the three Chinese herbal medicines: salvia miltiorrhiza, notoginseng and borneol:
- the compound Danshen dropping pills of the present invention are prepared from the following weight percentages of the drug substance relative to the total weight of the three Chinese herbal medicines: salvia miltiorrhiza, notoginseng and borneol:
- the compound Danshen dropping pills of the present invention are made of the following weight percent of the drug substance relative to the total weight of the three Chinese herbal medicines: salvia miltiorrhiza, notoginseng and borneol:
- the drug substance is relative to the excipient, and the drug substance is the active ingredient in the preparation.
- raw material medicine refers to raw medicine or traditional Chinese medicine decoction pieces that have not been further purified.
- the excipient refers to the collective name of all the medicinal materials except the bulk drug added to the prescription in order to solve the formability, effectiveness, stability and safety of the preparation during the formulation design of the preparation.
- the Salvia miltiorrhiza is the dry root and rhizome of the dicotyledon Labiatae salvia mi'to'orr/w'zfl Bge. Danshen can be sliced or crushed for use.
- the Panax notoginseng refers to the dried roots and rhizomes of Panax notoginseng (Burk.) FH Chen of the Araliaceae plant.
- the borneol is a crystal obtained by extracting the resin of the dipterocarp plant Dipterocarp and the volatile oil processed product, and can also be obtained by chemical synthesis, and can be finely sieved and used before use.
- the preparation of the traditional Chinese medicine composition of the present invention can be prepared by a prior art method, for example, Chinese patent application
- Danshen, Sanqi medicine, boiled water or alkaline water can be boiled, filtered, the filtrate is combined, and the filtrate is appropriately concentrated; ethanol is added to the concentrate for alcohol precipitation, and the supernatant is allowed to recover ethanol.
- the compound danshen dropping pills can be prepared according to the following steps: The Danshen and Sanqi medicinal materials are weighed according to the above ratio, and heated and refluxed in water or an aqueous solution of pH 7-9 for 2-4 times, each extraction is 0.5-3 hours. , the reflux extraction temperature is 60-100 ° C, the weight of each added water is 2-12 times the weight of the medicinal material, the obtained extract is filtered, the filtrate is concentrated to a relative density of 1.05-1.25, and the alcohol content of the ethanol is added to the liquid medicine. 50%-85% (v/v), let stand for 4 to 36 hours, filter the supernatant, recover the ethanol, and collect the extract to a sugar content of 50-90 brix ( ⁇ , Danshen Sanqi extract);
- the matrix adjuvant used in the compound Danshen dropping pill of the present invention may be polyethylene glycol-6000, and its freezing point is 53-58 ° C, and the ratio of the weight of the raw material drug to the auxiliary material is 1: (0.31-0.49)
- the mixture i.e., the chemical
- the molten medicine is dropped into a low-temperature cooling liquid (for example, liquid paraffin) to remove the cooling liquid, and the pellet is selected.
- the temperature of the chemical is 60-100 ° C; the temperature of the coolant is 0-10 ° C, preferably 5-10 ° C.
- the compound Danshen dropping pill of the present invention contains an auxiliary material which may be only a matrix auxiliary material or a combination of a matrix auxiliary material and a plasticizing auxiliary material.
- the matrix adjuvant used may also be a natural matrix adjuvant of plant origin, for example, may be selected from pharmaceutically acceptable D-ribose, fructose, xylose, trehalose, raffinose, maltose, agarose, sucrose ester, D -ribonic acid- ⁇ -lactone, erythritol, sorbitol, xylitol, arabinol, isomalt, lactitol, malic acid, glyceryl stearate, shellac, phenylethylene glycol, poly An oxyethylene decyl ether, and the above compound containing water of crystallization; the auxiliary material may further include a plasticizing auxiliary material, which may be selected, for example, from pregelatinized starch, carboxy, carb
- the compound Danshen dropping pill may be a vegetarian pill or a coated pill.
- the specific preparation method of the compound pellet of the compound danshen dropping pill can be, for example:
- the specific preparation method of the coated pellet of the compound danshen dropping pill can be, for example:
- the compound Danshen dripping pill capsule of the present invention produced an unexpected effect and was further proved by the following experiment.
- the experimental capsule shell was purchased from Sino-US joint venture Suzhou Capsule Co., Ltd. and is one of the production bases of Pfizer Capsule (CAPSUGEL).
- Capsule shells of different colors and materials were selected to contain compound Danshen dropping pills as test samples.
- the contents of various components of Danshen, Sanqi and Borneol were detected by HPLC, UV and GC in the environment of intense light irradiation and accelerated test.
- MMM Stability Test Case
- the compound Danshen Xiao Drop Pills was selected as the test sample, and the production line of Tianjin Tianshili Pharmaceutical Co., Ltd. was used for dripping.
- the test samples were divided into two types: coated pill and vegetarian pill.
- the average pill weight of the small drop pill is 10mg, and the ordinary No. 1 capsule can be filled with 30-35 capsules.
- the coarsely pulverized Danshen and Sanqi medicinal materials are taken into the extraction tank, and 5 times of the water of the above-mentioned Danshen and Sanqi medicinal materials is added, and the mixture is decocted for 2 hours, filtered, and the filter residue is subjected to the second extraction, and the above-mentioned Danshen and Sanqi medicinal materials are added. 4 times the amount of water, decocted for 1 hour, filtered, the filter residue was discarded, and the filtrate was combined.
- the filtrate was concentrated under reduced pressure to a relative density of 1.05, and 95% (v/v) ethanol was slowly added.
- the drug solution was subjected to an alcohol concentration of 69-71% (v/v) and allowed to stand for 12 hours.
- the supernatant of the liquid after the alcohol precipitation is filtered, and the filtrate is recovered into ethanol, and the extract is collected to an extract having a sugar content of 50 brix (ie, Danshen Sanqi extract).
- the average pill weight is 10mg/pill.
- the coarsely pulverized Danshen and Sanqi medicinal materials were taken into the extraction tank, and 5 times of the above-mentioned NaOH solution of Salvia miltiorrhiza and Radix Notoginseng was added to the NaOH aqueous solution of pH 9, and the mixture was decocted for 2 hours, filtered, and the filter residue was extracted for the second time.
- Four times the amount of the above alkaline solution of the medicinal materials of Panax notoginseng was boiled for 1 hour, filtered, and the filter residue was discarded, and the filtrate was combined.
- the filtrate was concentrated under reduced pressure to a relative density of 1.25, and 95% (v/v) of ethanol was slowly added to make the solution having an alcohol concentration of 69-71% (v/v) and allowed to stand for 12 hours.
- the supernatant of the liquid after the alcohol precipitation is filtered, and the filtrate is recovered to ethanol, and the extract is collected to an extract having a sugar content of 90 brix (i.e., Salvia miltiorrhiza extract).
- Capsule shells of gelatin and plant are used to cover 16 kinds of capsule shells of red, orange, yellow, green, cyan, blue and purple in the visible light range (Table 1).
- Table 1 Manufacturer number of capsule shell material and color
- the test is divided into two parts, the strong light irradiation test and the accelerated stability test.
- Accelerated test conditions temperature 40 ° C, relative humidity 75%. Samples were taken in October, January, February, March, April, and June.
- the capsules of the above 17 different colors and materials were selected to contain the compound Danshen dropping pills and the coated pills, and the degree of change of the compound Danshen dropping pills in the whole process of the accelerated test was investigated.
- Phase A Phase A: 0.02% (v/v) aqueous phosphoric acid
- Phase B Linear gradient elution procedure with 80% acetonitrile in 0.02% (v/v) phosphoric acid: Omin (90: 10), 8 min (78: 22), 15min (74:26), 35min (61:39) Flow rate lml/min, detection wavelength 280nm, column temperature 30 °C.
- each indicator component in Salvia miltiorrhiza Bge. is: 5.842 min of Danshensu, 9.750 min of protocatechuic aldehyde, and L is salvianolic acid. 17.106min, salvianolic acid M was 18.041min, salvianolic acid D was 20.588min, rosmarinic acid 24.005min, salvianolic acid B was 27.908min, and salvianolic acid A was 31.085min.
- Phase A 0.01% (v/v) aqueous acetic acid
- phase B aqueous solution of acetonitrile containing 0.01% (v/v) acetic acid.
- the linear gradient elution procedure is shown in the following table:
- the flow rate was 0.8 ml/min, the detection wavelength was 203 nm, and the column temperature was 30 °C.
- the retention time of each indicator component in Sanqi is: R1 is 11.001min, Rgl+Re is 12.252min, Rbl is 20.142min,
- Rc was 20.877 min
- Rb2 was 22.418 min
- Rb3 was 23.422 min
- Rd was 25.151 min.
- the protocatechuic aldehyde solution is a reference solution, and 0.3 wt% sodium dodecylsulfonate and 0.6% potassium ferricyanide solution and 0.9 wt% ferric chloride solution are added to the reference solution, the sample solution and the blank control solution. Using the color reaction, the total phenolic acid content in the sample was calculated according to the comparison method of the reference substance.
- the ginsenoside Rgl solution was used as a reference solution, and a coloring reaction was carried out by adding 5 wt% vanillin-glacial acetic acid solution and perchloric acid, and a standard curve was prepared by taking the absorbance of the standard solution of different concentrations to calculate the total saponin content in the sample.
- Glucose was used as the reference solution, and the fluorenone reagent was added to develop a color reaction.
- the standard curve was prepared by the absorbance of the standard solution of different concentrations, and the total sugar content in the sample was calculated. 3.3.4 Determination of borneol content
- the naphthalene standard was used as the internal standard solution, and the standard solution was prepared from the borneol and isobornyl standards.
- the injection amount was lul.
- the efficiency evaluation model is used to evaluate the advantages and disadvantages of the packaging.
- the method used in the process is Data Envelopment Analysis (DEA).
- the specific model is the super-efficiency model.
- the different packages are used as the object of investigation.
- the initial indicators of different packages are used as input objects, and the measured values of different indicators are measured for each month.
- the output object is calculated by MYDEA software to obtain the component retention efficiency of each package in different months. The less the component loss, the higher the efficiency value, and vice versa.
- the 19 indicator components are 8 indicator components of Salvia miltiorrhiza (Table 3), 7 components of Panax 7 (Table 4), and 3 major components (total phenolic acid, total saponin and total sugar). (Table 5); and borneol (Table 6).
- Table 4 The three-seven parts of nine different color capsule shell samples
- the protective effect on the contents of the capsule shell is more preferably the capsule shell of the capsule than the shell of the gelatin capsule.
- the strong light has an effect on the components of the compound Danshen dropping pills, and the protective ability of the capsule shells of different colors is different, but as long as it is a colored capsule shell The content will be protected, and the opaque white is ranked at the bottom of both the significant indicator and the score of all indicators.
- the experimental data also enables sorting of different color capsule shells.
- the preferred colors are: orange-yellow-green-blue-capsule shells, corresponding to a wavelength range of 446 nm to 620 nm.
- the orange system has a corresponding wavelength range of (592 nm to 620 nm); the blue system has a corresponding wavelength range of (446 nm to 500 nm); the yellow system has a corresponding wavelength range of 577 nm to 592 nm and a green color, and the corresponding wavelength range is 500 nm. -577nm.
- it can scatter medium-wavelength visible light (500-592nm), that is, yellow (corresponding wavelength range is 577nm-592nm) and green
- the capsule shell (corresponding to the wavelength range of 500nm-577n m ) has the strongest protective effect on the compound danshen dropping pills.
- the plant capsule shell is superior to the gelatin capsule shell;
- an orange-yellow-green-blue capsule shell is preferred, and the corresponding wavelength range is 446 nm-620 nm; More preferably, a yellow shell (corresponding to a wavelength range of 577 nm to 592 nm) and a green shell (corresponding to a wavelength range of 500 nm to 577 nm); (3) combining the above two considerations, preferably for a compound Danshen dripping pill capsule
- the capsule shells are: plant yellow capsule shell, plant green capsule shell, gelatin yellow capsule shell and gelatin green capsule shell.
- the wavelength range can be appropriately relaxed to orange and blue.
- the compound Danshen dripping pill capsule of the present invention is beneficial for maintaining the physical and chemical properties of the compound Danshen dripping pills and the stability of the active ingredients.
- the pharmaceutical ingredient was prepared in the same manner as in Example 1. After the pill was obtained, the 572 nm green plant capsule shell was wrapped.
- the pharmaceutical composition was prepared in the same manner as in Example 1. After the pellet was obtained, a plant capsule shell having a wavelength of 500 nm was coated.
- the pharmaceutical composition was prepared in the same manner as in Example 1. After obtaining the pellet, it was wrapped with a 592 nm yellow plant capsule shell.
- the pharmaceutical composition was prepared in the same manner as in Example 1. After the pellet was obtained, a plant capsule shell having a wavelength of 577 nm was coated.
- the pharmaceutical ingredient was prepared in the same manner as in Example 1. After the pill was obtained, a plant capsule shell having a wavelength of 592 nm was coated.
- the pharmaceutical composition was prepared in the same manner as in Example 1. After the pellet was obtained, an orange plant capsule shell of 620 nm was coated.
- the pharmaceutical composition was prepared in the same manner as in Example 1. After the pellet was obtained, a blue 466 nm plant capsule shell was wrapped.
- the pharmaceutical composition was prepared in the same manner as in Example 1. After the pellet was obtained, a yellow plant capsule shell of 580 nm was coated.
- the pharmaceutical composition was prepared in the same manner as in Example 1. After obtaining the pellet, it was wrapped with a 460 nm blue plant capsule shell.
- the pharmaceutical composition was prepared in the same manner as in Example 1. After the pellet was obtained, a green plant capsule shell of 550 nm was coated.
- the filtrate was concentrated under reduced pressure to a relative density of 1.25, and 95% (v/v) of ethanol was gradually added to make the drug solution having an alcohol concentration of 69-71% (v/v) and allowed to stand for 12 hours.
- the supernatant of the alcohol solution was taken, filtered, and the filtrate was recovered to ethanol, and the extract was collected to an extract having a sugar content of 90 brix.
- the pharmaceutical composition in the same manner as in Example 12, was coated with a 572 nm green plant capsule shell.
- the pharmaceutical composition was prepared in the same manner as in Example 12, and the plant capsule shell having a wavelength of 500 nm was coated.
- the pharmaceutical composition in the same manner as in Example 12, was wrapped with a 592 nm yellow plant capsule shell.
- the pharmaceutical composition in the same manner as in Example 12, was coated with a plant capsule shell having a wavelength of 577 nm.
- the pharmaceutical composition was prepared in the same manner as in Example 12, and the plant capsule shell having a wavelength of 592 nm was coated.
- the pharmaceutical composition in the same manner as in Example 12, was coated with a 620 nm orange plant capsule shell.
- the pharmaceutical composition in the same manner as in Example 12, was wrapped with a 446 nm blue plant capsule shell.
- the pharmaceutical composition in the same manner as in Example 12, was coated with a 580 nm yellow plant capsule shell.
- the pharmaceutical composition in the same manner as in Example 12, was coated with a 460 nm blue plant capsule shell.
- the pharmaceutical composition in the same manner as in Example 12, was coated with a 550 nm green plant capsule shell.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2789064A CA2789064C (en) | 2010-02-23 | 2011-02-17 | Capsule of compound danshen dripping pills |
JP2012554204A JP5926692B2 (ja) | 2010-02-23 | 2011-02-17 | 複方タンジン滴丸剤のカプセル剤 |
MX2012009688A MX353835B (es) | 2010-02-23 | 2011-02-17 | Capsulas de pildoras por goteo de compuesto dashen. |
AU2011220206A AU2011220206B2 (en) | 2010-02-23 | 2011-02-17 | Capsule of compound danshen dripping pills |
CN201180004827.4A CN102686220B (zh) | 2010-02-23 | 2011-02-17 | 复方丹参滴丸胶囊 |
BR112012021088A BR112012021088B8 (pt) | 2010-02-23 | 2011-02-17 | cápsula de pílulas de gotejamento à base de danshen |
EP11746831.4A EP2540285B1 (en) | 2010-02-23 | 2011-02-17 | Capsule of complex danshen drop pill |
ES11746831.4T ES2580838T3 (es) | 2010-02-23 | 2011-02-17 | Cápsula de píldora sublingual compleja de Danshen |
KR20157003296A KR20150018908A (ko) | 2010-02-23 | 2011-02-17 | 복합 단삼 점적 환제의 캡슐 |
EA201201117A EA026761B1 (ru) | 2010-02-23 | 2011-02-17 | Капсула с микрогранулами даншен |
US13/579,762 US9205123B2 (en) | 2010-02-23 | 2011-02-17 | Capsule of compound danshen dripping pills |
NZ60277111A NZ602771A (en) | 2010-02-23 | 2011-02-17 | Capsule of compound danshen dripping pills |
KR1020127024756A KR101652394B1 (ko) | 2010-02-23 | 2011-02-17 | 복합 단삼 점적 환제의 캡슐 |
HK12107383A HK1166695A1 (en) | 2010-02-23 | 2012-07-26 | Capsule of complex danshen drop pill |
IL221200A IL221200A (en) | 2010-02-23 | 2012-07-31 | Densics Complex Capsule |
ZA2012/06502A ZA201206502B (en) | 2010-02-23 | 2012-08-29 | Capsule of complex danshen dripping pill |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010112014.4 | 2010-02-23 | ||
CN2010101120144A CN102160872A (zh) | 2010-02-23 | 2010-02-23 | 复方丹参滴丸胶囊 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011103789A1 true WO2011103789A1 (zh) | 2011-09-01 |
Family
ID=44462496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/071050 WO2011103789A1 (zh) | 2010-02-23 | 2011-02-17 | 复方丹参滴丸胶囊 |
Country Status (21)
Country | Link |
---|---|
US (1) | US9205123B2 (zh) |
EP (1) | EP2540285B1 (zh) |
JP (1) | JP5926692B2 (zh) |
KR (2) | KR20150018908A (zh) |
CN (2) | CN102160872A (zh) |
AR (1) | AR080238A1 (zh) |
AU (1) | AU2011220206B2 (zh) |
BR (1) | BR112012021088B8 (zh) |
CA (1) | CA2789064C (zh) |
DO (1) | DOP2012000226A (zh) |
EA (1) | EA026761B1 (zh) |
ES (1) | ES2580838T3 (zh) |
HK (1) | HK1166695A1 (zh) |
HU (1) | HUE027756T2 (zh) |
IL (1) | IL221200A (zh) |
MX (1) | MX353835B (zh) |
MY (1) | MY169488A (zh) |
NZ (1) | NZ602771A (zh) |
PT (1) | PT2540285T (zh) |
WO (1) | WO2011103789A1 (zh) |
ZA (1) | ZA201206502B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015503572A (ja) * | 2012-01-04 | 2015-02-02 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドTasly Pharmaceutical Group Co., Ltd. | 肝線維症に関連する疾患の治療用薬剤の調製におけるラディックス・サルビアエ・ミルチオルヒザエ(タンジン)又はその製剤の使用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102160872A (zh) | 2010-02-23 | 2011-08-24 | 天津天士力制药股份有限公司 | 复方丹参滴丸胶囊 |
CN102920837A (zh) * | 2012-10-31 | 2013-02-13 | 侯明晓 | 一种治疗心律失常的中药及其制备工艺和应用 |
WO2015003659A1 (zh) * | 2013-07-11 | 2015-01-15 | 天士力制药集团股份有限公司 | 一种中药组合物及其制剂和用途 |
US9439867B1 (en) | 2015-03-13 | 2016-09-13 | Timing Pharmaceutical Co., Ltd. | Method for manufacturing a compound danshen dripping pill |
CN106539690B (zh) * | 2015-09-18 | 2020-08-04 | 天士力医药集团股份有限公司 | 一种液体冷却滴丸的连续智能制备方法 |
RU2633747C1 (ru) * | 2016-05-16 | 2017-10-17 | Александр Александрович Кролевец | Способ получения нанокапсул семян чиа (Salvia hispanica) в геллановой камеди |
CN107490594A (zh) * | 2016-06-13 | 2017-12-19 | 天士力制药集团股份有限公司 | 一种复方丹参滴丸提取物的氢核磁共振检测方法 |
CN110274962B (zh) * | 2018-03-13 | 2022-10-18 | 天士力医药集团股份有限公司 | 一种芪参益气滴丸中丹参多酚酸成分含量测定方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1066780A (zh) * | 1991-05-13 | 1992-12-09 | 国家医药管理局上海医药工业研究院 | 胶囊填充小型、微型片剂制备工艺 |
CN1348815A (zh) * | 2001-11-09 | 2002-05-15 | 天津天士力制药股份有限公司 | 一种预防和治疗冠心病心绞痛的药物及其制备方法和其它用途 |
CN1723998A (zh) * | 2005-07-16 | 2006-01-25 | 叶耀良 | 一种复方丹参新制剂及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU432703A3 (zh) | 1971-08-24 | 1974-06-15 | Фридрих Боссерт, Вульф Фатер, Курт Бауер | |
US8486464B2 (en) * | 2000-12-22 | 2013-07-16 | Tasly Pharmaceutical Group Co. Ltd. | Herbal composition for angina pectoris, method to prepare same and uses thereof |
US7670612B2 (en) * | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
CN1264533C (zh) * | 2002-06-07 | 2006-07-19 | 上海祥鹤制药厂 | 一种复方丹参胶囊及制备方法 |
US20050037094A1 (en) | 2003-07-31 | 2005-02-17 | Xijun Yan | Composition for heart disease, its active ingredients, method to prepare same and uses thereof |
JP2007504099A (ja) * | 2003-08-28 | 2007-03-01 | 天津天士力制薬股▲ふん▼有限公司 | 丹参、その抽出物および組成物を用いたアスピリン耐性の治療 |
CN100339085C (zh) * | 2003-09-23 | 2007-09-26 | 天津天士力制药股份有限公司 | 治疗心脑血管疾病的中药组合物 |
EP1593376A1 (en) * | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
CN1778336B (zh) | 2004-11-26 | 2011-04-27 | 天津天士力制药股份有限公司 | 一种复方丹参滴丸的制备方法 |
JP5308160B2 (ja) * | 2005-11-15 | 2013-10-09 | 景▲かい▼ 程 | 前立腺疾病及び皮膚癌におけるイソチオシアネート系化合物の使用 |
CN101091725A (zh) * | 2006-06-23 | 2007-12-26 | 天津天士力制药股份有限公司 | 一种中药颗粒及其制备方法 |
CN101717384B (zh) * | 2009-11-24 | 2011-10-12 | 正大青春宝药业有限公司 | 丹参注射液中的化合物及其在心血管疾病治疗中的应用 |
CN102160872A (zh) | 2010-02-23 | 2011-08-24 | 天津天士力制药股份有限公司 | 复方丹参滴丸胶囊 |
-
2010
- 2010-02-23 CN CN2010101120144A patent/CN102160872A/zh active Pending
-
2011
- 2011-02-17 NZ NZ60277111A patent/NZ602771A/xx active Application Filing
- 2011-02-17 MY MYPI2012003432A patent/MY169488A/en unknown
- 2011-02-17 HU HUE11746831A patent/HUE027756T2/en unknown
- 2011-02-17 JP JP2012554204A patent/JP5926692B2/ja active Active
- 2011-02-17 WO PCT/CN2011/071050 patent/WO2011103789A1/zh active Application Filing
- 2011-02-17 KR KR20157003296A patent/KR20150018908A/ko not_active IP Right Cessation
- 2011-02-17 CN CN201180004827.4A patent/CN102686220B/zh active Active
- 2011-02-17 EP EP11746831.4A patent/EP2540285B1/en active Active
- 2011-02-17 BR BR112012021088A patent/BR112012021088B8/pt active IP Right Grant
- 2011-02-17 MX MX2012009688A patent/MX353835B/es active IP Right Grant
- 2011-02-17 PT PT117468314T patent/PT2540285T/pt unknown
- 2011-02-17 US US13/579,762 patent/US9205123B2/en active Active
- 2011-02-17 AU AU2011220206A patent/AU2011220206B2/en active Active
- 2011-02-17 ES ES11746831.4T patent/ES2580838T3/es active Active
- 2011-02-17 KR KR1020127024756A patent/KR101652394B1/ko active IP Right Grant
- 2011-02-17 CA CA2789064A patent/CA2789064C/en active Active
- 2011-02-17 EA EA201201117A patent/EA026761B1/ru not_active IP Right Cessation
- 2011-02-21 AR ARP110100528 patent/AR080238A1/es not_active Application Discontinuation
-
2012
- 2012-07-26 HK HK12107383A patent/HK1166695A1/xx unknown
- 2012-07-31 IL IL221200A patent/IL221200A/en active IP Right Grant
- 2012-08-17 DO DO2012000226A patent/DOP2012000226A/es unknown
- 2012-08-29 ZA ZA2012/06502A patent/ZA201206502B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1066780A (zh) * | 1991-05-13 | 1992-12-09 | 国家医药管理局上海医药工业研究院 | 胶囊填充小型、微型片剂制备工艺 |
CN1348815A (zh) * | 2001-11-09 | 2002-05-15 | 天津天士力制药股份有限公司 | 一种预防和治疗冠心病心绞痛的药物及其制备方法和其它用途 |
CN1723998A (zh) * | 2005-07-16 | 2006-01-25 | 叶耀良 | 一种复方丹参新制剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
FRIDRUN PODCZECK ET AL., PHARMACEUTICAL CAPSULE, SECOND EDITION 2004, PHARMACEUTICAL PRESS, 2004 * |
See also references of EP2540285A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015503572A (ja) * | 2012-01-04 | 2015-02-02 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドTasly Pharmaceutical Group Co., Ltd. | 肝線維症に関連する疾患の治療用薬剤の調製におけるラディックス・サルビアエ・ミルチオルヒザエ(タンジン)又はその製剤の使用 |
US9895405B2 (en) | 2012-01-04 | 2018-02-20 | Tasly Pharmaceutical Group Co., Ltd. | Use of radix salviae miltiorrhizae (danshen) or its preparations in preparation of drugs for treating diseases related to hepatic fibrosis |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011103789A1 (zh) | 复方丹参滴丸胶囊 | |
BRPI0616319A2 (pt) | composiÇço e mÉtodo para extrair uma espÉcie de panax | |
Singh | Medicinal plants of the world | |
CN103071006A (zh) | 一种治疗肾功能衰竭中药的制备方法及质量检测方法 | |
CN102240322B (zh) | 一种复方丹参片及其制备工艺 | |
CN104614450B (zh) | 一种消渴清制剂的指纹图谱检测方法 | |
CN104910112B (zh) | 一种中药丹参有效成分丹酚酸b的制备方法、药物制剂及临床应用 | |
CN103054946B (zh) | 一种复方丹参片的逆流提取工艺及其制备工艺 | |
CN101209341B (zh) | 一种中药制剂及其制备方法和检测方法 | |
CN110302297A (zh) | 一种蒙药及其颗粒剂和制备方法 | |
TWI571257B (zh) | Capsule preparation | |
CN114099609B (zh) | 一种治疗咳嗽的药物组合物及其制备方法 | |
CN102309543B (zh) | 复方丹参浓缩制剂及其制备、检测方法 | |
CN102038869B (zh) | 中药制剂保幼化风丹的检测方法 | |
CN101455674B (zh) | 用于治疗慢性肝炎的椭圆叶花锚总双苯吡喃酮滴丸及其制备方法 | |
CN107014945B (zh) | 一种治疗急性传染性肝炎的中药制剂的检测方法 | |
CN111298050A (zh) | 一种午时茶挥发油脂质体制备工艺、产品及其检测方法 | |
CN118021750B (zh) | 一种清咽利喉胶囊的制备方法 | |
CN101766800B (zh) | 感冒疏风丸的质量检测方法 | |
CN101850013A (zh) | 一种治疗感冒的中药滴鼻剂及其制剂质控方法和应用 | |
CN111407790A (zh) | 一种降香挥发油的包合方法及舒心宁片的制备方法 | |
CN112569300A (zh) | 用于降血糖的组合物、制剂、其制备方法及应用 | |
CN111973669A (zh) | 一种清肺止咳的蒙药及其制备方法 | |
CN111983045A (zh) | 一种治疗冠心病的蒙药的质量控制方法 | |
CN107929132A (zh) | 青蒿粉的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180004827.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11746831 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011220206 Country of ref document: AU Ref document number: 221200 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2789064 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011746831 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13579762 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/009688 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2011220206 Country of ref document: AU Date of ref document: 20110217 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012554204 Country of ref document: JP Ref document number: 1201004241 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7531/CHENP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201201117 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 20127024756 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012021088 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012021088 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120822 |